Philippe Pouletty is co-founder and General Director of Truffle Capital.
Biotech and Medtech industry veteran with dual experience in Silicon Valley and in France.
Founder and Chairman of Deinove (Alternext: ALDEI), Co-founder and Board member of Carbios, Co-founder and Board member of Carmat (Alternext: ALCAR), former chairman and Board member of Neovacs (Alternext: ALNEV), Chairman of Splicos, co-founder and Board member of Pharnext, Plasmaprime, Vexim, Wittycell, Board member of Immune Targeting Systems, Myopowers, Symetis, Theraclion, Theradiag (Alternext: ALTER) all Truffle Capital portfolio companies.
Independent Board member of Innate Pharma (Euronext). Founder of SangStat (1988, organ transplantation therapeutics, IPO on NASDAQ in 1993, sold to Genzyme for $600M in 2002), Conjuchem (founded in 1993, IPO on the Toronto stock exchange in 2000). Former Chairman (2001-2009) and Honorary Chairman of France Biotech, the French biotech industry association. Inventor of the Young Innovative Entreprise Status (JEI), implemented by President Chirac in 2004 in France. Former vice chairman of Europabio, the European biotech industry association.
Inventor of 29 patents, including the second highest revenue generating life science patent for Stanford University. He thus entered the prestigious Stanford University Hall of Fame of Inventors in 2012.
MD from the University of Paris VI, hematology and immunology resident in Paris hospital, MS degrees in immunology (with honours) and virology from Pasteur Institute, post-doctoral research fellow (1986-1988) at Stanford University. 1999 laureate of the American Liver Foundation. Chevalier de la Légion d’Honneur.